South Carolina is currently home to 1173 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Spartanburg and Columbia. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT04262466
Recruiting
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Prisma Health, Greenville, South Carolina
Conditions: Select Advanced Solid Tumors
Register for Updates
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
NCT03253263
Recruiting
The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
Gender:
ALL
Ages:
Between 0 hours and 24 hours
Trial Updated:
07/22/2025
Locations: Medical University of South Carolina Children Hospital, Charleston, South Carolina
Conditions: Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
Register for Updates
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
NCT02954094
Recruiting
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Hepatocellular Cancer
Register for Updates
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
NCT02815891
Recruiting
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
07/22/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Register for Updates
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
NCT01915511
Recruiting
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the th... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
07/22/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Gender:
ALL
Ages:
All
Trial Updated:
07/22/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Register for Updates
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
NCT06738017
Recruiting
The goal of this clinical trial is to assess the safety and tolerability of a single oral dose of BMN 349 in participants with PiZZ or PiMZ/MASH. Primary outcome measures include incidence of any adverse events (including serious adverse events, dose limit toxicities, and adverse events of special interest), incidence of any laboratory test abnormalities, incidence of lung function test abnormalities and 12-lead ECG parameters. Participants will receive a single dose of either BMN 349 or place... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/21/2025
Locations: The Medical University of South Carolina, Charleston, South Carolina
Conditions: Alpha 1-Antitrypsin Deficiency
Register for Updates
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
NCT06635785
Recruiting
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Prisma Health, Greenville, South Carolina
Conditions: Advanced Solid Tumor
Register for Updates
Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant
NCT05654922
Recruiting
The goal of this Phase 3 clinical trial is to compare ARINA-1 (a nebulized immunomodulatory agent) plus Standard of Care vs Standard of Care alone. The main question it aims to answer are: * Evaluate the effectiveness of ARINA-1 in preventing bronchiolitis obliterans syndrome (BOS) progression in participants with a bilateral lung transplant * To evaluate the effectiveness of ARINA-1 on improving quality of life decline and preventing or delaying the use of augmented immunosuppression in partic... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/21/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Pre-Bronchiolitis Obliterans Syndrome
Register for Updates
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NCT04301843
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Gender:
ALL
Ages:
31 years and below
Trial Updated:
07/21/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Neuroblastoma
Register for Updates
Steroids and Pain Control After Tonsillectomy
NCT03995628
Recruiting
This research study aims to find out if a single oral dose of steroid after tonsillectomy will reduce pain and decrease the need for narcotic medications.
Gender:
ALL
Ages:
Between 3 years and 12 years
Trial Updated:
07/21/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Tonsillitis, Obstructive Sleep Apnea of Child
Register for Updates
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690
Recruiting
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2025
Locations: Retina Consultants of Carolina, Greenville, South Carolina
Conditions: Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Register for Updates